Published online before print January 30, 2003, doi: 10.1161/01.ATV.0000058402.34138.11
© 2003 American Heart Association, Inc.
Atherosclerosis and Lipoproteins |
Obesity and Systemic Oxidative Stress
Clinical Correlates of Oxidative Stress in The Framingham Study
From the Evans Memorial Department of Medicine (J.F.K. R.S.V., P.W.F.W., J.A.V., E.J.B.), Whitaker Cardiovascular Institute (J.F.K., I.L., J.A.V.), and Department of Preventive Medicine (R.S.V., E.J.B.), Boston University School of Medicine; Department of Epidemiology and Biostatistics (J.M.M.), Boston University School of Public Health; and the National Heart, Lung, and Blood Institute Framingham Study (M.G.L., R.S.V., P.W.F.W., D.C., J.M.M., P.S., E.J.B.), Framingham, MA.
Correspondence to J.F. Keaney, Jr, Boston University School of Medicine, Whitaker Cardiovascular Institute, 715 Albany St, Rm W507, Boston, MA 02118. E-mail jkeaney{at}bu.edu
 |
Abstract |
|---|
 Top Abstract IntroductionMaterials and MethodsResultsDiscussionReferences |
|---|
Objective— To determine the clinical conditions associated with systemic oxidative stress in a community-based cohort. Information regarding cardiovascular risk factors associated with systemic oxidative stress has largely been derived from highly selected samples with advanced stages of vascular disease. Thus, it has been difficult to evaluate the relative contribution of each cardiovascular risk factor to systemic oxidative stress and to determine whether such risk factors act independently and are applicable to the general population.
Methods and Results— We examined 2828 subjects from the Framingham Heart Study and measured urinary creatinine–indexed levels of 8-epi-PGF2
as a marker of systemic oxidative stress. Age- and sex-adjusted multivariable regression models were used to assess clinical correlates of oxidative stress. In age- and sex-adjusted models, increased urinary creatinine–indexed 8-epi-PGF2 levels were positively associated with female sex, hypertension treatment, smoking, diabetes, blood glucose, body mass index, and a history of cardiovascular disease. In contrast, age and total cholesterol were negatively correlated with urinary creatinine–indexed 8-epi-PGF2 levels. After adjustment for several covariates, decreasing age and total/HDL cholesterol ratio, sex, smoking, body mass index, blood glucose, and cardiovascular disease remained associated with urinary 8-epi-PGF2 levels.
Conclusions— Smoking, diabetes, and body mass index were highly associated with systemic oxidative stress as determined by creatinine-indexed urinary 8-epi-PGF2 levels. The effect of body mass index was minimally affected by blood glucose, and diabetes and may suggest an important role of oxidative stress in the deleterious impact of obesity on cardiovascular disease.
Key Words: oxidative stress • isoprostanes • diabetes • obesity • cardiovascular disease
|
Introduction |
|---|
|
TopAbstractIntroductionMaterials and MethodsResultsDiscussionReferences |
|---|
Oxidative damage has been implicated in the pathogenesis of many chronic progressive diseases, such as cancer, inflammation, and neurodegenerative disorders. Over the last decade, there has been considerable interest in the role of oxidative stress in vascular disease as well. This interest has been driven by a wealth of data indicating that LDL1 oxidation is a prominent feature of atherosclerosis (for review, see references1). More recently, studies have also suggested that oxidative stress is a feature of many risk factors for premature atherosclerosis, such as diabetes,2 hypertension,3 and smoking.4
See pages 365 and 368
By and large, clinical studies linking oxidative stress to atherosclerosis and its risk factors have involved small, highly selected groups of patients in the advanced stages of disease. This selectivity is the result, in part, of the limited consensus for reliable markers of oxidative stress. Over the last decade, however, there has been considerable progress in characterizing markers of lipid peroxidation that are derived from arachidonic acid.5 This class of compounds, known as isoprostanes, have now been established as reliable markers of oxidative stress in a number of experimental and clinical settings (for review, see references6) As with many markers of oxidative damage, early studies with isoprostanes were limited in scope by the technical demands of sample processing for gas chromatography-mass spectrometry. However, a reliable ELISA for specific isoprostanes has recently been developed.7
The availability of such methodology now makes it feasible to address a number of important questions. For example, the relative magnitude with which individual atherosclerosis risk factors contribute to markers of oxidative stress is unknown. In addition, the extent to which hypertension, diabetes, and smoking contribute independently to systemic oxidative stress is also unknown. Finally, the relation between oxidative stress and atherosclerosis risk factors has not been tested in relatively healthy populations. The purpose of this study, therefore, was to examine the clinical correlates of systemic oxidative stress in a large community-based cohort.
|
Materials and Methods |
|---|
|
TopAbstractIntroductionMaterials and MethodsResultsDiscussionReferences |
|---|
Study Sample
The design and selection criteria of the Framingham Study have been extensively described elsewhere.8 The current study sample was derived from the Offspring cohort that began in 1971 with recruitment of 5124 men and women who were offspring or spouses of the offspring of the original Framingham cohort. The 3537 participants who attended the seventh offspring examination cycle (1998 to 2001) were eligible for the present investigation. All attendees underwent routine medical history and physical examination, laboratory assessment of cardiovascular risk factors, and obesity measurements, including height, weight, waist, and hip circumference. Clinical definition for diabetes included fasting glucose greater than or equal to 126 mg/dL, oral hypoglycemic use, or insulin use. Information about cardiovascular disease (CVD; eg, coronary heart disease, cerebrovascular disease, intermittent claudication, congestive heart failure) events was obtained with the aid of medical histories, physical examinations at the Heart Study (every 4 years), hospitalization records, and by communication with personal physicians. All suspected cardiovascular events were reviewed by a panel of three experienced investigators who evaluated all pertinent medical records. Criteria for these end points have been described previously.9 Subjects were excluded from this study for the following reasons: attended examination before routine collection of urine (n=378); unavailable urine (n=329); other (n=2). After exclusions, a total of 2828 subjects remained eligible for the current investigation.
Determination of 8-Epi-PGF2
As an index of systemic oxidative stress, we used the urinary content of 8-epi-PGF2, one of many stable products of arachidonic acid formed on nonenzymatic oxidation.6 Urine samples were used because they contain very little arachidonic acid, thereby limiting artifactual oxidation and isoprostane production after sample collection. Urine samples (3 mL) were collected and temporarily stored at -4°C for up to 4 hours and then maintained at -20°C (for creatinine) or -80°C (for isoprostanes) until analysis. Preliminary experiments demonstrated that collection of samples in this manner had no material impact on the content of 8-epi-PGF2. For analysis, samples were thawed at room temperature, vortexed vigorously, and the content of 8-epi-PGF2 determined using a commercially available ELISA (Cayman, Ann Arbor, MI). Samples analyzed in this manner correlate well with those analyzed using electrospray-negative ionization gas chromatography-mass spectroscopy (GC/MS).7 Samples were analyzed in duplicate with an average intra-assay coefficient of variation of 9.7%. Any samples with a CV greater than two standard deviations from this mean (21%) were repeated. Urinary creatinine was run on an Abbott Spectrum CCX using a method based on the reaction of creatinine and alkaline picrate according to the manufacturer’s instructions with average intra- and interassay coefficients of variation of 2% and 4%, respectively. A sample was repeated using the following criteria: 1) if the mean creatinine level was below 50 mg/100 mL and the difference between the two repeats was greater than 4.0 mg/100 mL 2) or if the mean creatinine level was above or equal to 50 mg/100 mL and the percent difference between the two repeats was greater than 6.5%. Urinary content of 8-epi-PGF2 was indexed to creatinine and expressed as ng/mmol creatinine.
Statistical Analysis
The distribution of urinary creatinine–indexed 8-epi-PGF2 levels was highly skewed; therefore, further analyses were performed with natural logarithmic transformation of the data. The urinary isoprostanes were measured over 7 months using two different lots from Cayman Chemicals. Using internal controls that were run on every plate, a difference between lots was detected (P<0.001); subsequently, all analyses were adjusted for the effect of the lot. Ninety-four phantom samples were analyzed along with the rest of the 8-epi-PGF2 samples. Kappa analysis was performed on quartiles of these phantoms versus their known counterparts. The weighted Kappa coefficient was 0.80 showing good reproducibility.
Age- and sex-adjusted linear regression models were constructed to assess association of each of the following possible clinical correlates individually: total cholesterol, systolic blood pressure, diastolic blood pressure, body mass index (BMI), fasting glucose level, history of diabetes, smoking, hypertension treatment, and history of myocardial infarction or CVD. Sex interactions were also tested for each variable listed above. Stepwise multivariable models were performed with log creatinine–indexed 8-epi-PGF2 against the above variables plus total cholesterol to HDL cholesterol ratio. Correlations among siblings were also studied in age, sex, and multivariable models. Analyses were run using the statistical package SAS version 8.1, (PROC REG and PROC MIXED).10 Any two-sided probability value less than 0.05 was considered to be statistically significant.
|
Results |
|---|
|
TopAbstractIntroductionMaterials and MethodsResultsDiscussionReferences |
|---|
Subject Characteristics and Individual Predictors of Urinary 8-Epi-PGF2
LevelsThe characteristics of subjects in this study are displayed in Table 1. The mean age of the participants was 61 years, 55% of whom were women. As expected, a greater proportion of men had prevalent CVD than did women. On average, women exhibited urinary creatinine–indexed 8-epi-PGF2
levels that were 16% higher than men (P<0.001; Table 1). This finding was not simply a consequence of higher urinary creatinine levels in men because women had higher urinary 8-epi-PGF2 levels at each decile of urinary creatinine (data not shown).
|
Both age and sex were important clinical correlates of urinary creatinine–indexed 8-epi-PGF2 levels, with age demonstrating an inverse relation to this estimate of systemic oxidative stress. We performed age- and sex-adjusted regression using clinical and laboratory variables from Table 1 as correlates of urinary creatinine-indexed 8-epi-PGF2, and these results are contained in Table 2. Data for men and women are combined because we found no significant interaction on the basis of sex. Both smoking and diabetes were strongly and positively associated with an increase in urinary 8-epi-PGF2, which is consistent with previous reports.2,4 We also observed a strong association between BMI and urinary 8-epi-PGF2 levels (Table 2). Although animal studies suggest that hypertension11 and hypercholesterolemia12 may be associated with systemic oxidative stress, we found only weak relations between these two clinical conditions and urinary creatinine–indexed 8-epi-PGF2 levels.
|
Multivariable Correlates of Creatinine-Indexed Urinary 8-Epi-PGF2 Levels
The results of multivariable regression models using clinical and laboratory variables are contained in Table 3. Age was marginally significant in the multivariable model. The strongest positive predictor of urinary creatinine–indexed 8-epi-PGF2 was smoking, with smokers demonstrating a 65% higher mean level than nonsmokers (raw mean levels of 240±145, and 148±100 ng/mmol creatinine in smokers and nonsmokers, respectively). Fasting glucose was also associated with our estimate of systemic oxidative stress. Each 25 mg/dL increase in fasting glucose was associated with a 4.3% increase in urinary creatinine–indexed 8-epi-PGF2 levels. Diabetes and serum glucose were correlated; when diabetes was substituted for serum glucose in the multivariable model, individuals with a diagnosis of diabetes demonstrated urinary creatinine–indexed 8-epi-PGF2 levels that were 10.8% higher than nondiabetics, with raw means being 181±128 ng/mmol creatinine versus 157±108 ng/mmol creatinine. In the multivariable model, total cholesterol to HDL cholesterol ratio also emerged as a negative correlate of 8-epi-PGF2 levels (P<0.0001).
|
In addition to smoking and diabetes, our data support a relation between obesity and creatinine-indexed urinary levels of 8-epi-PGF2. With respect to BMI, we found that each 5 kg/m2 was associated with a 9.9% increase in urinary creatinine–indexed 8-epi-PGF2 levels. To ensure this relation was truly a reflection of obesity, we substituted waist to hip ratio for BMI in the multivariable model and found it was also significantly associated with creatinine-indexed urinary 8-epi-PGF2 levels (P<0.0001). To characterize the relation between obesity and oxidative stress, we plotted creatinine-indexed 8-epi-PGF2 as a function of BMI quintile in nonsmokers and these data are contained in the Figure. Overall, the multivariable model was able to explain approximately 15.8% of the variability in urinary creatinine–indexed 8-epi-PGF2. The most important contributors to the multivariable model were smoking, BMI, sex, glucose, total cholesterol to HDL cholesterol ratio, and prevalent CVD that contributed 7.7%, 2.4%, 2.2%, 0.5%, 0.6%, and 0.3%, respectively, to explaining variability of urinary creatinine–indexed 8-epi-PGF2 levels.
|
We performed several secondary analyses to ensure that our findings were not confounded by the presence of illness or medication treatment. We found that excluding patients with CVD or on lipid-lowering medication had no material effect on the results contained in Table 3. If we excluded patients on hypertension treatment, systolic blood pressure gained a marginal positive association with urinary 8-epi-PGF2 levels (P=0.07). With respect to heritability, we found a sibling correlation of 0.06, indicating modest heritability (roughly 12%). Taking into account siblings in the multivariable model had no material impact on the analyses listed in Table 3.
|
Discussion |
|---|
|
TopAbstractIntroductionMaterials and MethodsResultsDiscussionReferences |
|---|
Considerable evidence links CVD and its risk factors to increased oxidative stress, although such evidence is derived from selected samples of individuals with advanced cardiovascular risk factors or disease. Thus, the extent to which this evidence applies to healthier populations is unclear. The principal finding of this study is that systemic oxidative stress, estimated as creatinine-indexed urinary 8-epi-PGF2
, is related to smoking, diabetes, and obesity in a large community-based cohort. In contrast, adjusted analyses did not demonstrate any strong positive association between creatinine-indexed urinary 8-epi-PGF2 levels and other variables, such as total cholesterol, blood pressure, or age. In fact, with respect to the latter, age appeared associated with a decrease in this marker of systemic oxidative stress.
Previous studies have established a link between smoking and oxidative stress. Cigarette smoke is replete with a number of oxidizing species capable of producing lipid peroxidation.13 Consistent with this notion, smokers typically demonstrate reduced circulating levels of vitamin C, an important antioxidant in human plasma.14 Morrow and colleagues4 demonstrated that both plasma levels and urinary metabolites of F2-isoprostanes (of which 8-epi-PGF2 is a member) are increased in smokers compared with age- and sex-matched controls. In that study, plasma-free isoprostanes in smokers were 
1.4-fold greater than in nonsmokers. In this study, we found a 65% increase in isoprostanes as a function of smoking, in good agreement with the published data.4 This finding represents an important internal control for our study as the relation between smoking and isoprostanes as a marker of oxidative stress is well established.4,15–17
In addition to smoking, we found a significant positive association between creatinine-indexed urinary 8-epi-PGF2 and both clinical diabetes and fasting glucose levels (Table 3). These data are in good agreement with previous smaller studies linking hyperglycemia with increased levels of 8-epi-PGF22 and lipid hydroperoxides,18 two markers of lipid peroxidation. Similarly, urinary levels of 8-epi-PGF2 are increased in patients with both types I and II diabetes and decrease significantly with aggressive control of hyperglycemia.19 Several mechanisms have been proposed to explain this link between hyperglycemia and lipid peroxidation. Glucose may combine directly with LDL phospholipids or apo B lysine groups to form advanced glycosylation end products that facilitate lipid peroxidation.20 In addition, autoxidation of glucose and nonenzymatic glycation of proteins may generate superoxide,21 a radical species implicated in vascular cell–mediated LDL oxidation.22 Hyperglycemia also induces the enzymatic production of superoxide through activation of NAD(P)H oxidase in vascular cells.23 Our data support this basic research and suggest the effect of glucose on oxidative stress is applicable to a relatively healthy community-based cohort.
Among the more novel findings of the current study was the positive association between indices of obesity, such as BMI and waist/hip ratio and urinary levels of 8-epi-PGF2. These data agree with a smaller studies linking BMI with plasma isoprostanes24,25 and other markers of oxidative stress such as reduced erythrocyte glutathione and glutathione peroxidase.26 The notion that obesity is associated with a state of heightened oxidative stress is not without precedent. Obesity is associated with insulin resistance,27 and emerging evidence links insulin resistance to oxidative stress.28 For example, hydrogen peroxide impairs insulin signaling29 and inhibits glucose transport,30 two cardinal features of insulin resistance. Moreover, tumor necrosis factor-, a cytokine known to induce insulin resistance, mediates its effect through hydrogen peroxide generation.31 Insulin itself promotes hydrogen peroxide generation in fat cells,32 prompting speculation that oxidative stress is a principal mechanism of insulin resistance with chronic hyperinsulinemia. Thus, the data presented here are in good agreement with basic investigation concerning insulin and oxidative stress.
Total cholesterol was weakly inversely associated with urinary 8-epi-PGF2 levels in both age- and sex-adjusted and multivariable models. This finding may be puzzling to some because previous studies have linked hypercholesterolemia33–35 to excess oxidative stress. In this regard, such studies typically have involved small numbers of patients (<38) often with extreme hypercholesterolemia typical of FH patients.33–36 In contrast, our study involved many more subjects and total cholesterol levels more typical for a Western population (200 mg/dL).37 With respect to the former, we were able to construct multivariable models to control for confounding, whereas previous studies did not.33–36 With respect to differences in cholesterol levels, it is possible the relation between cholesterol and oxidative stress described by other studies is not applicable to "average" cholesterol levels. There is one study by Reilly and colleagues36 linking moderate hypercholesterolemia with urinary excretion of both 8-epi-PGF2 and class VI isoprostanes in 24 patients. That study sample differed significantly from ours in that the mean age was younger (41 years), smokers were excluded, and the average total cholesterol was higher (290 mg/dL). Moreover, in that study, the control group (serum cholesterol 170 mg/dL) did not demonstrate any relation between cholesterol levels and urinary isoprostanes.36 Considering that cholesterol levels from our sample more closely resemble the control group from that study,36 one might speculate that study sample differences explain these discrepant results.
In contrast to previous animal studies,38 we did not find any meaningful positive association between a marker of oxidative stress and hypertension (Table 3). Systolic blood pressure was marginally and positively associated with urinary 8-epi-PGF2 levels in age- and sex-adjusted models but not in the multivariable stepwise model. Animal data suggest the association of hypertension with oxidative stress may only apply to certain hypertensive states, such as those associated with high renin levels11 or salt sensitivity.39 Because the determinants of blood pressure in our sample are likely multifactorial, the proportion with oxidative stress–mediated hypertension may be too small to drive an association between hypertension and oxidative stress. Alternatively, because approximately one third of our subjects were receiving antihypertensive therapy, we may have lost the discriminatory value of blood pressure as a correlate of oxidative stress. This concern is mitigated somewhat by the secondary analysis in which we excluded patients on hypertensive treatment and still did not observe a strong association between blood pressure and urinary creatinine–indexed 8-epi-PGF2 levels. Perhaps the development of more sophisticated means of classifying hypertension may help resolve this issue.
Another surprising feature of this study was the negative correlation between aging and oxidative stress estimated as creatinine-indexed 8-epi-PGF2 levels. A number of experimental studies in humans and animals have linked aging to a state of heightened oxidative stress (reviewed in the references40), in apparent contradiction to the current results. We believe the current investigation still must be viewed favorably in comparison with such previous data as much of that data involved small samples predominantly with case-control designs,40 whereas this cross-sectional investigation involved a large sample not selected on the basis of disease or other characteristics. Furthermore, we were able to construct multivariable models to control for confounding, whereas smaller studies typically involve too few subjects for such analysis. Nevertheless, aging is associated with changes in total body fat mass, circulating free fatty acids, and renal function, all of which could conceivably alter the value of creatinine-indexed urinary levels of 8-epi-PGF2. Further investigation will be required to determine the precise relation between aging and this marker of lipid peroxidation.
Finally, we found that urinary levels of 8-epi-PGF2 were significantly higher in women than in men. We expected this finding was caused by the lower levels of urinary creatinine in women compared with men (Table 1), however, even at similar levels of urinary creatinine, we found that 8-epi-PGF2 levels in urine were higher in women. Our data agree with a smaller study of 298 healthy subjects aged 19 to 78 years by Block and colleagues24 in which plasma levels of 8-epi-PGF2 were also higher in women than in men. Thus, both our data and that of Block and colleagues appear to challenge contemporary dogma that men exhibit increased evidence of oxidative stress compared with women.41
There are several limitations of the present study that warrant consideration. First and foremost, we used a spot analysis of urinary 8-epi-PGF2 as an index of oxidative stress rather than a 24-hour collection. This choice was necessitated by the constraints inherent in a large epidemiological investigation where there is a need to ensure compliance among participants. Nevertheless, it is possible that other markers of oxidative stress may provide additional information that was not detected in this study. Additionally, because the sample was derived from a single measurement in ambulatory volunteers, 8-epi-PGF2 levels may have been confounded by medication status. Another limitation of this study was our use of an ELISA rather than GC/MS, the gold standard for isoprostane analysis. This compromise was driven by the need to process large numbers of samples in a timely manner. However, previous studies have demonstrated a significant correlation between the two methods (r=0.63).7 It is also worth noting that a less precise ELISA (compared with GC/MS) would result in a random misclassification of levels and this would bias us toward the null hypothesis, that is, tend to weaken associations between variables and urinary 8-epi-PGF2 levels. As such, the associations reported in this study would likely be stronger if an assay with a better signal-to-noise ratio were used. Another limitation of the present study is that our study sample was predominantly white, so our results may not be generalizable to other ethnicities. Finally, one must consider that 8-epi-PGF2 may not be the best choice in future studies as a urinary marker of oxidative stress. For example, Li and colleagues33 have shown that other isoprostanes are more abundant in urine than 8-epi-PGF2 and that not all clinical conditions display the same pattern of urinary isoprostane excretion.
In summary, the results reported here indicate that smoking, diabetes, and obesity are strong independent predictors of systemic oxidative stress when the latter is measured as creatinine-indexed urinary levels of 8-epi-PGF2. These data suggest that obesity is associated with a state of excess oxidative stress and suggest yet another contributing mechanism for excess CVD with obesity.
|
Acknowledgments |
|---|
This study was supported by NIH/NHLBI contracts N01-HC-25195 and the NIH Boston University Cardiovascular Center, N01-HV-28178 and NIH grants HL64753 (E.J.B.), DK55656 (J.F.K.), HL60886 (J.A.V and J.F.K), and HL71039 (R.S.V.). Dr. Keaney is an Established Investigator of the American Heart Association, and Dr. Vasan is the recipient of a research career award (HL04334) from the NIH.
|
Footnotes |
|---|
In the Framingham Heart Study, we found that decreasing age, prevalent cardiovascular disease, female sex, smoking, blood glucose, and body mass index were independently associated with oxidative stress measured as urinary creatinine-indexed 8-epi-PGF2
levels. These data suggest an important role of oxidative stress in the deleterious impact of obesity on cardiovascular disease. Received November 22, 2002; accepted January 16, 2003.
|
References |
|---|
|
TopAbstractIntroductionMaterials and MethodsResultsDiscussionReferences |
|---|
1. Witztum JL, Steinberg D. Role of oxidized low density lipoprotein in atherogenesis. J Clin Invest. 1991; 88: 1785–1792.
2. Gopaul NK, Änggård EE, Mallet AI, Betteridge DJ, Wolff SP, Nourooz-Zadeh J. Plasma 8-epi-PGF2alpha levels are elevated in individuals with non-insulin dependent diabetes mellitus. FEBS Lett. 1995; 368: 225–229.[CrossRef][Medline] [Order article via Infotrieve]
3. Griendling KK, Sorescu D, Ushio-Fukai M. NAD(P)H oxidase: role in cardiovascular biology and disease. Circ Res. 2000; 86: 494–501.
4. Morrow JD, Frei B, Longmire AW, Gaziano JM, Lynch SM, Shyr Y, Strauss WE, Oates JS, Roberts LJ. Increase in circulating products of lipid peroxidation (F2-isoprostanes) in smokers: smoking as a cause of oxidative damage. N Engl J Med. 1995; 332: 1198–1203.
5. Morrow JD, Hill KE, Burk RF, Nammour TM, Badr KF, Roberts LJ. A series of prostaglandin F2-like compounds are produced in vivo in humans by a non-cyclooxygenase, free radical-catalyzed mechanism. Proc Natl Acad Sci U S A. 1990; 87: 9383–9387.
6. Roberts LJ, Morrow JD. The generation and actions of isoprostanes. Biochim Biophys Acta. 1997; 1345: 121–135.[Medline] [Order article via Infotrieve]
7. Proudfoot J, Barden A, Mori TA, Burke V, Croft KD, Beilin LJ, Puddey IB. Measurement of urinary F(2)-isoprostanes as markers of in vivo lipid peroxidation-A comparison of enzyme immunoassay with gas chromatography/mass spectrometry. Anal Biochem. 1999; 272: 209–215.[CrossRef][Medline] [Order article via Infotrieve]
8. Kannel WB, Feinleib M, McNamara PM, Garrison RJ, Castelli WP. An investigation of coronary heart disease in families: the Framingham offspring study. Am J Epidemiol. 1979; 110: 281–290.
9. The Framingham Study.In: Kannel WB, Wolf PA, Garrison RJ, eds. An Epidemiological Investigation of Cardiovascular Disease,Section 34. (NIH) 87–2703. Bethesda, MD: National Heart, Lung, and Blood Institute; 1987.
10. SAS/STAT User’s Guide, Version 8. Cary, NC: SAS Institute, Inc.; 1999.
11. Laursen JB, Rajagopalan S, Galis ZS, Tarpey M, Freeman BA, Harrison DG. Role of superoxide in angiotensin II-induced but not catecholamine-induced hypertension. Circulation. 1997; 95: 588–593.
12. Ohara Y, Peterson TE, Harrison DG. Hypercholesterolemia increases endothelial superoxide anion production. J Clin Invest. 1993; 91: 2546–2551.
13. Frei B, Forte TM, Ames BN, Cross CE. Gas phase oxidants of cigarette smoke induce lipid peroxidation and changes in lipoprotein properties in human blood plasma. Biochem J. 1991; 277: 133–138.
14. Frei B, England L, Ames BN. Ascorbate is an outstanding antioxidant in human blood plasma. Proc Natl Acad Sci U S A. 1989; 86: 6377–6381.
15. Pilz H, Oguogho A, Chehne F, Lupattelli G, Palumbo B, Sinzinger H. Quitting cigarette smoking results in a fast improvement of in vivo oxidation injury (determined via plasma, serum and urinary isoprostane). Thromb Res. 2000; 99: 209–221.[CrossRef][Medline] [Order article via Infotrieve]
16. [Increased plasma level of lipid peroxidation products (F2-isoprostanes) in smokers]. Dtsch Med Wochenschr. 1995; 120: 1107.
17. Chehne F, Oguogho A, Lupattelli G, Budinsky AC, Palumbo B, Sinzinger H. Increase of isoprostane 8-epi-PGF2 after restarting smoking. Prostaglandins Leukot Essent Fatty Acids. 2001; 64: 307–310.[CrossRef][Medline]
[Order article via Infotrieve]
18. Nourooz-Zadeh J, Tajaddini-Sarmadi J, Mccarthy S, Betteridge DJ, Wolff SP. Elevated levels of authentic plasma hydroperoxides in NIDDM. Diabetes. 1995; 44: 1054–1058.[Abstract]
19. Davi G, Ciabottoni G, Consoli A, Messetti A, Falco A, Santarone S, Pennese E, Vitacolonna E, Bucciarelli T, Costantini F, Capani F, Patrono C. In vivo formation of 8-iso-prostaglandin F2 and platelet activation in diabetes mellitus: effects of improved metabolic control. Circulation. 1999; 99: 224–229.
20. Bucala R, Makita Z, Koschinsky T, Cerami A, Vlassara H. Lipid advanced glycosylation: pathway for lipid oxidation in vivo. Proc Natl Acad Sci U S A. 1993; 90: 6434–6438.
21. Baynes JW. Role of oxidative stress in the development of complications in diabetes. Diabetes. 1991; 40: 405–412.[Abstract]
22. Heinecke JW, Baker L, Rosen H, Chait A. Superoxide mediated modification of low density lipoprotein by human arterial smooth muscle cells in culture. J Clin Invest. 1986; 77: 757–761.
23. Inoguchi T, Li P, Umeda F, Yu HY, Kakimoto M, Imamura M, Aoki T, Etoh T, Hashimoto T, Naruse M, Sano H, Utsumi H, Nawata H. High glucose level and free fatty acid stimulate reactive oxygen species production through protein kinase C–dependent activation of NAD(P)H oxidase in cultured vascular cells. Diabetes. 2000; 49: 1939–1945.[Abstract]
24. Block G, Dietrich M, Norkus EP, Morrow JD, Hudes M, Caan B, Packer L. Factors associated with oxidative stress in human populations. Am J Epidemiol. 2002; 156: 274–285.
25. Dietrich M, Block G, Hudes M, Morrow JD, Norkus EP, Traber MG, Cross CE, Packer L. Antioxidant supplementation decreases lipid peroxidation biomarker F2-isoprostanes in plasma of smokers. Cancer Epidemiol Biomarkers Prev. 2002; 11: 7–13.
26. Trevisan M, Browne R, Ram M, Muti P, Freudenheim J, Carosella AM, Armstrong D. Correlates of markers of oxidative status in the general population. Am J Epidemiol. 2001; 154: 348–356.
27. Baron AD. Impaired glucose tolerance as a disease. Am J Cardiol. 2001; 88: 16H-19H.[Medline] [Order article via Infotrieve]
28. Facchini FS, Hua NW, Reaven GM, Stoohs RA. Hyperinsulinemia: the missing link among oxidative stress and age- related diseases? Free Radic Biol Med. 2000; 29: 1302–1306.[CrossRef][Medline] [Order article via Infotrieve]
29. Rudich A, Kozlovsky N, Potashnik R, Bashan N. Oxidant stress reduces insulin responsiveness in 3T3-L1 adipocytes. Am J Physiol. 1997; 272: E935–E940.
30. Rudich A, Tirosh A, Potashnik R, Hemi R, Kanety H, Bashan N. Prolonged oxidative stress impairs insulin-induced GLUT4 translocation in 3T3-L1 adipocytes. Diabetes. 1998; 47: 1562–1569.[Abstract]
31. Hansen LL, Ikeda Y, Olsen GS, Busch AK, Mosthaf L. Insulin signaling is inhibited by micromolar concentrations of H2O2: evidence for a role of H2O2 in tumor necrosis factor alpha-mediated insulin resistance. J Biol Chem. 1999; 274: 25078–25084.
32. Krieger-Brauer HI, Kather H. Human fat cells possess a plasma membrane-bound H2O2-generating system that is activated by insulin via a mechanism bypassing the receptor kinase. J Clin Invest. 1992; 89: 1006–1013.
33. Li H, Lawson JA, Reilly M, Adiyaman M, Hwang SW, Rokach J, FitzGerald GA. Quantitative high performance liquid chromatography/tandem mass spectrometric analysis of the four classes of F2-isoprostanes in human urine. Proc Natl Acad Sci U S A. 1999; 96: 13381–13386.
34. Oguogho A, Ferlitsch A, Sinzinger H, LDL-apheresis decreases plasma levels and urinary excretion of 8-epi-PGF2. Prostaglandins Leukot Essent Fatty Acids. 2000; 62: 209–216.[CrossRef][Medline]
[Order article via Infotrieve]
35. Cracowski JL, Ploin D, Bessard J, Baguet JP, Stanke-Labesque F, Mallion JM, Bost M, Bessard G. Formation of isoprostanes in children with type IIa hypercholesterolemia. J Cardiovasc Pharmacol. 2001; 38: 228–231.[CrossRef][Medline] [Order article via Infotrieve]
36. Reilly MP, Pratico D, Delanty N, DiMinno G, Tremoli E, Rader D, Kapoor S, Rokach J, Lawson J, FitzGerald GA. Increased formation of distinct F2 isoprostanes in hypercholesterolemia. Circulation. 1998; 98: 2822–2828.
37. Kannel WB. Range of serum cholesterol values in the population developing coronary artery disease. Am J Cardiol. 1995; 76: 69C-77C.[CrossRef][Medline] [Order article via Infotrieve]
38. Reckelhoff JF, Zhang H, Srivastava K, Roberts LJ, Morrow JD, Romero JC. Subpressor doses of angiotensin II increase plasma F(2)-isoprostanes in rats. Hypertension. 2000; 35: 476–479.
39. Somers MJ, Mavromatis K, Galis ZS, Harrison DG. Vascular superoxide production and vasomotor function in hypertension induced by deoxycorticosterone acetate-salt. Circulation. 2000; 101: 1722–1728.
40. Hensley K, Floyd RA. Reactive oxygen species and protein oxidation in aging: a look back, a look ahead. Arch Biochem Biophys. 2002; 397: 377–383.[CrossRef][Medline] [Order article via Infotrieve]
41. Ide T, Tsutsui H, Ohashi N, Hayashidani S, Suematsu N, Tsuchihashi M, Tamai H, Takeshita A. Greater oxidative stress in healthy young men compared with premenopausal women. Arterioscler Thromb Vasc Biol. 2002; 22: 438–442.
This article has been cited by other articles:
 |
|
 |
|
  W. T. McNicholas Chronic Obstructive Pulmonary Disease and Obstructive Sleep Apnea: Overlaps in Pathophysiology, Systemic Inflammation, and Cardiovascular Disease Am. J. Respir. Crit. Care Med., October 15, 2009; 180(8): 692 - 700. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 A. Sood, C. Qualls, A. Arynchyn, W. S. Beckett, M. D. Gross, M. W. Steffes, L. J. Smith, P. Holvoet, B. Thyagarajan, and D. R. Jacobs Jr Obesity-Asthma Association: Is It Explained by Systemic Oxidant Stress? Chest, October 1, 2009; 136(4): 1055 - 1062. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 J. Koskinen, M. Kahonen, J. S.A. Viikari, L. Taittonen, T. Laitinen, T. Ronnemaa, T. Lehtimaki, N. Hutri-Kahonen, M. Pietikainen, E. Jokinen, et al. Conventional Cardiovascular Risk Factors and Metabolic Syndrome in Predicting Carotid Intima-Media Thickness Progression in Young Adults: The Cardiovascular Risk in Young Finns Study Circulation, July 21, 2009; 120(3): 229 - 236. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 L. Lavie and P. Lavie Molecular mechanisms of cardiovascular disease in OSAHS: the oxidative stress link Eur. Respir. J., June 1, 2009; 33(6): 1467 - 1484. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 D.-E. Lee, S. Kehlenbrink, H. Lee, M. Hawkins, and J. S. Yudkin Getting the message across: mechanisms of physiological cross talk by adipose tissue Am J Physiol Endocrinol Metab, June 1, 2009; 296(6): E1210 - E1229. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 Q. Dai, Y.-T. Gao, X.-O. Shu, G. Yang, G. Milne, Q. Cai, W. Wen, N. Rothman, H. Cai, H. Li, et al. Oxidative Stress, Obesity, and Breast Cancer Risk: Results From the Shanghai Women's Health Study J. Clin. Oncol., May 20, 2009; 27(15): 2482 - 2488. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 L. J. Roberts II and G. L. Milne Isoprostanes J. Lipid Res., April 1, 2009; 50(Supplement): S219 - S223. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
G. L. Pierce, L. A. Lesniewski, B. R. Lawson, S. D. Beske, and D. R. Seals Nuclear Factor-{kappa}B Activation Contributes to Vascular Endothelial Dysfunction via Oxidative Stress in Overweight/Obese Middle-Aged and Older Humans Circulation, March 10, 2009; 119(9): 1284 - 1292. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 D. S. Frankel, R. S. Vasan, R. B. D'Agostino Sr, E. J. Benjamin, D. Levy, T. J. Wang, and J. B. Meigs Resistin, Adiponectin, and Risk of Heart Failure: The Framingham Offspring Study J. Am. Coll. Cardiol., March 3, 2009; 53(9): 754 - 762. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 N. Bashan, J. Kovsan, I. Kachko, H. Ovadia, and A. Rudich Positive and Negative Regulation of Insulin Signaling by Reactive Oxygen and Nitrogen Species Physiol Rev, January 1, 2009; 89(1): 27 - 71. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 D. T. Smith, L. J. Carr, C. Dorozynski, and C. Gomashe Internet-delivered lifestyle physical activity intervention: limited inflammation and antioxidant capacity efficacy in overweight adults J Appl Physiol, January 1, 2009; 106(1): 49 - 56. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
D. S. Frankel, J. B. Meigs, J. M. Massaro, P. W.F. Wilson, C. J. O'Donnell, R. B. D'Agostino, and G. H. Tofler Von Willebrand Factor, Type 2 Diabetes Mellitus, and Risk of Cardiovascular Disease: The Framingham Offspring Study Circulation, December 9, 2008; 118(24): 2533 - 2539. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 W. MacNee, J. Maclay, and D. McAllister Cardiovascular Injury and Repair in Chronic Obstructive Pulmonary Disease Proceedings of the ATS, December 1, 2008; 5(8): 824 - 833. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 L. Garrido-Sanchez, J. M. Garcia-Almeida, S. Garcia-Serrano, I. Cardona, J. Garcia-Arnes, F. Soriguer, F. J. Tinahones, and E. Garcia-Fuentes Improved Carbohydrate Metabolism After Bariatric Surgery Raises Antioxidized LDL Antibody Levels in Morbidly Obese Patients Diabetes Care, December 1, 2008; 31(12): 2258 - 2264. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 D. Alkazemi, G. Egeland, J. Vaya, S. Meltzer, and S. Kubow Oxysterol as a Marker of Atherogenic Dyslipidemia in Adolescence J. Clin. Endocrinol. Metab., November 1, 2008; 93(11): 4282 - 4289. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 J. Y. Kim, Y. J. Hyun, Y. Jang, B. K. Lee, J. S. Chae, S. E. Kim, H. Y. Yeo, T.-S. Jeong, D. W. Jeon, and J. H. Lee Lipoprotein-associated phospholipase A2 activity is associated with coronary artery disease and markers of oxidative stress: a case-control study Am. J. Clinical Nutrition, September 1, 2008; 88(3): 630 - 637. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 Y. S. Lee, A Y. Kim, J. W. Choi, M. Kim, S. Yasue, H. J. Son, H. Masuzaki, K. S. Park, and J. B. Kim Dysregulation of Adipose Glutathione Peroxidase 3 in Obesity Contributes to Local and Systemic Oxidative Stress Mol. Endocrinol., September 1, 2008; 22(9): 2176 - 2189. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 S. Ashfaq, J. L. Abramson, D. P. Jones, S. D. Rhodes, W. S. Weintraub, W. C. Hooper, V. Vaccarino, R. W. Alexander, D. G. Harrison, and A. A. Quyyumi Endothelial Function and Aminothiol Biomarkers of Oxidative Stress in Healthy Adults Hypertension, July 1, 2008; 52(1): 80 - 85. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
G. L. Pierce, S. D. Beske, B. R. Lawson, K. L. Southall, F. J. Benay, A. J. Donato, and D. R. Seals Weight Loss Alone Improves Conduit and Resistance Artery Endothelial Function in Young and Older Overweight/Obese Adults Hypertension, July 1, 2008; 52(1): 72 - 79. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 G. L. Milne, H. Yin, and J. D. Morrow Human Biochemistry of the Isoprostane Pathway J. Biol. Chem., June 6, 2008; 283(23): 15533 - 15537. [Full Text] [PDF]
|
|
|
|
 |
|
 J. Muller-Ehmsen, D. Braun, T. Schneider, R. Pfister, N. Worm, K. Wielckens, C. Scheid, P. Frommolt, and M. Flesch Decreased number of circulating progenitor cells in obesity: beneficial effects of weight reduction Eur. Heart J., June 2, 2008; 29(12): 1560 - 1568. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 P. K. Reddy Thavanati, K. R. Kanala, A. E. de Dios, and J. M. Cantu Garza Age-Related Correlation Between Antioxidant Enzymes and DNA Damage With Smoking and Body Mass Index J. Gerontol. A Biol. Sci. Med. Sci., April 1, 2008; 63(4): 360 - 364. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 G. P. Van Guilder, B. L. Stauffer, J. J. Greiner, and C. A. DeSouza Impaired endothelium-dependent vasodilation in overweight and obese adult humans is not limited to muscarinic receptor agonists Am J Physiol Heart Circ Physiol, April 1, 2008; 294(4): H1685 - H1692. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 L. Lundholm, M. Putnik, M. Otsuki, S. Andersson, C. Ohlsson, J.-A. Gustafsson, and K. Dahlman-Wright Effects of estrogen on gene expression profiles in mouse hypothalamus and white adipose tissue: target genes include glutathione peroxidase 3 and cell death-inducing DNA fragmentation factor, {alpha}-subunit-like effector A J. Endocrinol., March 1, 2008; 196(3): 547 - 557. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 L. F. Ramos, A. Shintani, T. A. Ikizler, and J. Himmelfarb Oxidative Stress and Inflammation Are Associated with Adiposity in Moderate to Severe CKD J. Am. Soc. Nephrol., March 1, 2008; 19(3): 593 - 599. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M. K. Shea, S. L. Booth, J. M. Massaro, P. F. Jacques, R. B. D'Agostino Sr, B. Dawson-Hughes, J. M. Ordovas, C. J. O'Donnell, S. Kathiresan, J. F. Keaney Jr, et al. Vitamin K and Vitamin D Status: Associations with Inflammatory Markers in the Framingham Offspring Study Am. J. Epidemiol., February 1, 2008; 167(3): 313 - 320. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
T. M. Paravicini and R. M. Touyz NADPH Oxidases, Reactive Oxygen Species, and Hypertension: Clinical implications and therapeutic possibilities Diabetes Care, February 1, 2008; 31(Supplement_2): S170 - S180. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J B. Richards, A. M Valdes, J. P Gardner, D. Paximadas, M. Kimura, A. Nessa, X. Lu, G. L Surdulescu, R. Swaminathan, T. D Spector, et al. Higher serum vitamin D concentrations are associated with longer leukocyte telomere length in women Am. J. Clinical Nutrition, November 1, 2007; 86(5): 1420 - 1425. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J. B. Meigs, M. G. Larson, C. S. Fox, J. F. Keaney Jr., R. S. Vasan, and E. J. Benjamin Association of Oxidative Stress, Insulin Resistance, and Diabetes Risk Phenotypes: The Framingham Offspring Study Diabetes Care, October 1, 2007; 30(10): 2529 - 2535. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
C. A. Carnes, P. M. L. Janssen, M. L. Ruehr, H. Nakayama, T. Nakayama, H. Haase, J. A. Bauer, M. K. Chung, I. M. Fearon, A. M. Gillinov, et al. Atrial Glutathione Content, Calcium Current, and Contractility J. Biol. Chem., September 21, 2007; 282(38): 28063 - 28073. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
K. M. Pou, J. M. Massaro, U. Hoffmann, R. S. Vasan, P. Maurovich-Horvat, M. G. Larson, J. F. Keaney Jr, J. B. Meigs, I. Lipinska, S. Kathiresan, et al. Visceral and Subcutaneous Adipose Tissue Volumes Are Cross-Sectionally Related to Markers of Inflammation and Oxidative Stress: The Framingham Heart Study Circulation, September 11, 2007; 116(11): 1234 - 1241. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
I. R Hsu, S. P Kim, M. Kabir, and R. N Bergman Metabolic syndrome, hyperinsulinemia, and cancer Am. J. Clinical Nutrition, September 1, 2007; 86(3): 867S - 871S. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
T. Wu, W. C. Willett, N. Rifai, and E. B. Rimm Plasma Fluorescent Oxidation Products as Potential Markers of Oxidative Stress for Epidemiologic Studies Am. J. Epidemiol., September 1, 2007; 166(5): 552 - 560. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 F. Dong, Q. Li, N. Sreejayan, J. M. Nunn, and J. Ren Metallothionein Prevents High-Fat Diet Induced Cardiac Contractile Dysfunction: Role of Peroxisome Proliferator Activated Receptor {gamma} Coactivator 1{alpha} and Mitochondrial Biogenesis Diabetes, September 1, 2007; 56(9): 2201 - 2212. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. I. Frisard, A. Broussard, S. S. Davies, L. J. Roberts II, J. Rood, L. d. Jonge, X. Fang, S. M. Jazwinski, W. A. Deutsch, E. Ravussin, et al. Aging, Resting Metabolic Rate, and Oxidative Damage: Results From the Louisiana Healthy Aging Study J. Gerontol. A Biol. Sci. Med. Sci., July 1, 2007; 62(7): 752 - 759. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
W. Yan, G. D. Byrd, and M. W. Ogden Quantitation of isoprostane isomers in human urine from smokers and nonsmokers by LC-MS/MS J. Lipid Res., July 1, 2007; 48(7): 1607 - 1617. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 S. Musaad and E. N. Haynes Biomarkers of Obesity and Subsequent Cardiovascular Events Epidemiol. Rev., May 10, 2007; (2007) mxm005v1. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J. Uribarri, W. Cai, M. Peppa, S. Goodman, L. Ferrucci, G. Striker, and H. Vlassara Circulating Glycotoxins and Dietary Advanced Glycation Endproducts: Two Links to Inflammatory Response, Oxidative Stress, and Aging J. Gerontol. A Biol. Sci. Med. Sci., April 1, 2007; 62(4): 427 - 433. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 J. W. Rankin and A. D. Turpyn Low Carbohydrate, High Fat Diet Increases C-Reactive Protein during Weight Loss J. Am. Coll. Nutr., April 1, 2007; 26(2): 163 - 169. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 E. Nisoli, E. Clementi, M. O. Carruba, and S. Moncada Defective Mitochondrial Biogenesis: A Hallmark of the High Cardiovascular Risk in the Metabolic Syndrome? Circ. Res., March 30, 2007; 100(6): 795 - 806. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
K. L. Moreau, A. R. DePaulis, K. M. Gavin, and D. R. Seals Oxidative stress contributes to chronic leg vasoconstriction in estrogen-deficient postmenopausal women J Appl Physiol, March 1, 2007; 102(3): 890 - 895. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 J. P. Forman, E. B. Rimm, and G. C. Curhan Frequency of Analgesic Use and Risk of Hypertension Among Men Arch Intern Med, February 26, 2007; 167(4): 394 - 399. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 J. Ahn, C. B. Ambrosone, P. A. Kanetsky, C. Tian, T. A. Lehman, S. Kropp, I. Helmbold, D. von Fournier, W. Haase, M. L. Sautter-Bihl, et al. Polymorphisms in Genes Related to Oxidative Stress (CAT, MnSOD, MPO, and eNOS) and Acute Toxicities from Radiation Therapy following Lumpectomy for Breast Cancer Clin. Cancer Res., December 1, 2006; 12(23): 7063 - 7070. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 V. O. Palmieri, I. Grattagliano, P. Portincasa, and G. Palasciano Systemic Oxidative Alterations Are Associated with Visceral Adiposity and Liver Steatosis in Patients with Metabolic Syndrome J. Nutr., December 1, 2006; 136(12): 3022 - 3026. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
R. Stocker and M. A. Perrella Heme Oxygenase-1: A Novel Drug Target for Atherosclerotic Diseases? Circulation, November 14, 2006; 114(20): 2178 - 2189. [Full Text] [PDF]
|
|
|
|
|
|
I. Aeberli, L. Molinari, G. Spinas, R. Lehmann, D. l'Allemand, and M. B Zimmermann Dietary intakes of fat and antioxidant vitamins are predictors of subclinical inflammation in overweight Swiss children. Am. J. Clinical Nutrition, October 1, 2006; 84(4): 748 - 755. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 T. Okada, M. Miyashita, Y. Kuromori, F. Iwata, K. Harada, and H. Hattori Platelet-activating factor acetylhydrolase concentration in children with abdominal obesity. Arterioscler Thromb Vasc Biol, May 1, 2006; 26(5): e40 - e41. [Full Text] [PDF]
|
|
|
|
 |
|
 L. Monnier, E. Mas, C. Ginet, F. Michel, L. Villon, J.-P. Cristol, and C. Colette Activation of Oxidative Stress by Acute Glucose Fluctuations Compared With Sustained Chronic Hyperglycemia in Patients With Type 2 Diabetes JAMA, April 12, 2006; 295(14): 1681 - 1687. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 P. Rossner Jr., M. D. Gammon, M. B. Terry, M. Agrawal, F. F. Zhang, S. L. Teitelbaum, S. M. Eng, M. M. Gaudet, A. I. Neugut, and R. M. Santella Relationship between Urinary 15-F2t-Isoprostane and 8-Oxodeoxyguanosine Levels and Breast Cancer Risk. Cancer Epidemiol. Biomarkers Prev., April 1, 2006; 15(4): 639 - 644. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
E. B. Loucks, L. M. Sullivan, L. J. Hayes, R. B. D'Agostino Sr., M. G. Larson, R. S. Vasan, E. J. Benjamin, and L. F. Berkman Association of Educational Level with Inflammatory Markers in the Framingham Offspring Study Am. J. Epidemiol., April 1, 2006; 163(7): 622 - 628. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
N. R. Madamanchi and M. S. Runge Five Easy Pieces: The Obesity Paradigm Circ. Res., March 17, 2006; 98(5): 576 - 578. [Full Text] [PDF]
|
|
|
|
|
|
S. Ashfaq, J. L. Abramson, D. P. Jones, S. D. Rhodes, W. S. Weintraub, W. C. Hooper, V. Vaccarino, D. G. Harrison, and A. A. Quyyumi The Relationship Between Plasma Levels of Oxidized and Reduced Thiols and Early Atherosclerosis in Healthy Adults J. Am. Coll. Cardiol., March 7, 2006; 47(5): 1005 - 1011. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
P. Poirier, T. D. Giles, G. A. Bray, Y. Hong, J. S. Stern, F. X. Pi-Sunyer, and R. H. Eckel Obesity and Cardiovascular Disease: Pathophysiology, Evaluation, and Effect of Weight Loss: An Update of the 1997 American Heart Association Scientific Statement on Obesity and Heart Disease From the Obesity Committee of the Council on Nutrition, Physical Activity, and Metabolism Circulation, February 14, 2006; 113(6): 898 - 918. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
T. Weinbrenner, H. Schroder, V. Escurriol, M. Fito, R. Elosua, J. Vila, J. Marrugat, and M.-I. Covas Circulating oxidized LDL is associated with increased waist circumference independent of body mass index in men and women Am. J. Clinical Nutrition, January 1, 2006; 83(1): 30 - 35. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
A. Fortuno, G. San Jose, M. U. Moreno, O. Beloqui, J. Diez, and G. Zalba Phagocytic NADPH Oxidase Overactivity Underlies Oxidative Stress in Metabolic Syndrome Diabetes, January 1, 2006; 55(1): 209 - 215. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
D. Canoy, N. Wareham, A. Welch, S. Bingham, R. Luben, N. Day, and K.-T. Khaw Plasma ascorbic acid concentrations and fat distribution in 19 068 British men and women in the European Prospective Investigation into Cancer and Nutrition Norfolk cohort study Am. J. Clinical Nutrition, December 1, 2005; 82(6): 1203 - 1209. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J.-Y. Park, R. E. Ferrell, J.-J. Park, J. M. Hagberg, D. A. Phares, J. M. Jones, and M. D. Brown NADPH oxidase p22phox gene variants are associated with systemic oxidative stress biomarker responses to exercise training J Appl Physiol, November 1, 2005; 99(5): 1905 - 1911. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
H. J Thompson, J. Heimendinger, S. Sedlacek, A. Haegele, A. Diker, C. O'Neill, B. Meinecke, P. Wolfe, Z. Zhu, and W. Jiang 8-Isoprostane F2{alpha} excretion is reduced in women by increased vegetable and fruit intake Am. J. Clinical Nutrition, October 1, 2005; 82(4): 768 - 776. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
B. Buijsse, E. J. Feskens, D. Schlettwein-Gsell, M. Ferry, F. J Kok, D. Kromhout, L. C. de Groot, and for the SENECA investigators Plasma carotene and {alpha}-tocopherol in relation to 10-y all-cause and cause-specific mortality in European elderly: the Survey in Europe on Nutrition and the Elderly, a Concerted Action (SENECA) Am. J. Clinical Nutrition, October 1, 2005; 82(4): 879 - 886. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
G. E. Alvarez, B. M. Davy, T. P. Ballard, S. D. Beske, and K. P. Davy Weight loss increases cardiovagal baroreflex function in obese young and older men Am J Physiol Endocrinol Metab, October 1, 2005; 289(4): E665 - E669. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 U. Bernabucci, B. Ronchi, N. Lacetera, and A. Nardone Influence of Body Condition Score on Relationships Between Metabolic Status and Oxidative Stress in Periparturient Dairy Cows J Dairy Sci, June 1, 2005; 88(6): 2017 - 2026. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
K. L. Moreau, K. M. Gavin, A. E. Plum, and D. R. Seals Ascorbic Acid Selectively Improves Large Elastic Artery Compliance in Postmenopausal Women Hypertension, June 1, 2005; 45(6): 1107 - 1112. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J. P. Gardner, S. Li, S. R. Srinivasan, W. Chen, M. Kimura, X. Lu, G. S. Berenson, and A. Aviv Rise in Insulin Resistance Is Associated With Escalated Telomere Attrition Circulation, May 3, 2005; 111(17): 2171 - 2177. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
A. Mohn, M. Catino, R. Capanna, C. Giannini, M. Marcovecchio, and F. Chiarelli Increased Oxidative Stress in Prepubertal Severely Obese Children: Effect of a Dietary Restriction-Weight Loss Program J. Clin. Endocrinol. Metab., May 1, 2005; 90(5): 2653 - 2658. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
D. D. Christou, C. L. Gentile, C. A. DeSouza, D. R. Seals, and P. E. Gates Fatness Is a Better Predictor of Cardiovascular Disease Risk Factor Profile Than Aerobic Fitness in Healthy Men Circulation, April 19, 2005; 111(15): 1904 - 1914. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
A. F. Dominiczak, D. Graham, M. W. McBride, N. J.R. Brain, W. K. Lee, F. J. Charchar, M. Tomaszewski, C. Delles, and C. A. Hamilton Cardiovascular Genomics and Oxidative Stress Hypertension, April 1, 2005; 45(4): 636 - 642. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 E. M. Stuveling, S. J. L. Bakker, H. L. Hillege, P. E. de Jong, R. O. B. Gans, and D. de Zeeuw Biochemical risk markers: a novel area for better prediction of renal risk? Nephrol. Dial. Transplant., March 1, 2005; 20(3): 497 - 508. [Full Text] [PDF]
|
|
|
|
|
|
J. D. Morrow Quantification of Isoprostanes as Indices of Oxidant Stress and the Risk of Atherosclerosis in Humans Arterioscler Thromb Vasc Biol, February 1, 2005; 25(2): 279 - 286. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 I. S. Young Oxidative Stress and Vascular Disease: Insights from Isoprostane Measurement Clin. Chem., January 1, 2005; 51(1): 14 - 15. [Full Text] [PDF]
|
|
|
|
|
|
N. R. Madamanchi, A. Vendrov, and M. S. Runge Oxidative Stress and Vascular Disease Arterioscler Thromb Vasc Biol, January 1, 2005; 25(1): 29 - 38. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J. A. Vita, J. F. Keaney Jr, M. G. Larson, M. J. Keyes, J. M. Massaro, I. Lipinska, B. T. Lehman, S. Fan, E. Osypiuk, P. W.F. Wilson, et al. Brachial Artery Vasodilator Function and Systemic Inflammation in the Framingham Offspring Study Circulation, December 7, 2004; 110(23): 3604 - 3609. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 P. MONTUSCHI, P. J. BARNES, and L. J. ROBERTS II Isoprostanes: markers and mediators of oxidative stress FASEB J, December 1, 2004; 18(15): 1791 - 1800. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. Juonala, J. S.A. Viikari, T. Laitinen, J. Marniemi, H. Helenius, T. Ronnemaa, and O. T. Raitakari Interrelations Between Brachial Endothelial Function and Carotid Intima-Media Thickness in Young Adults: The Cardiovascular Risk in Young Finns Study Circulation, November 2, 2004; 110(18): 2918 - 2923. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
B. Hansel, P. Giral, E. Nobecourt, S. Chantepie, E. Bruckert, M. J. Chapman, and A. Kontush Metabolic Syndrome Is Associated with Elevated Oxidative Stress and Dysfunctional Dense High-Density Lipoprotein Particles Displaying Impaired Antioxidative Activity J. Clin. Endocrinol. Metab., October 1, 2004; 89(10): 4963 - 4971. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
R. Stocker and J. F. Keaney Jr. Role of Oxidative Modifications in Atherosclerosis Physiol Rev, October 1, 2004; 84(4): 1381 - 1478. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
F.-P. Xu, M.-S. Chen, Y.-Z. Wang, Q. Yi, S.-B. Lin, A. F. Chen, and J.-D. Luo Leptin Induces Hypertrophy via Endothelin-1-Reactive Oxygen Species Pathway in Cultured Neonatal Rat Cardiomyocytes Circulation, September 7, 2004; 110(10): 1269 - 1275. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
S. Mustafa, T. Vukovich, T. Prikoszovich, C. Winzer, B. Schneider, H. Esterbauer, O. Wagner, and A. Kautzky-Willer Haptoglobin Phenotype and Gestational Diabetes Diabetes Care, September 1, 2004; 27(9): 2103 - 2107. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
H. Shibata, T. Nabika, H. Moriyama, J. Masuda, and S. Kobayashi Correlation of NO Metabolites and 8-Iso-Prostaglandin F2a With Periventricular Hyperintensity Severity Arterioscler Thromb Vasc Biol, September 1, 2004; 24(9): 1659 - 1663. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
C. Vassalle, M. G. Andreassi, E. Schwedhelm, R. Maas, R. H. Boger, J. Brummer, J. Berger, A. Bartling, H. Lenzen, D. Tsikas, et al. 8-Iso-Prostaglandin F2{alpha} as a Risk Marker in Patients With Coronary Heart Disease * Response Circulation, August 3, 2004; 110(5): e49 - e50. [Full Text] [PDF]
|
|
|
|
 |
|
 G. Xing, T. Shimosawa, T. Ogihara, H. Matsui, K. Itakura, X. Qingyou, T. Asano, K. Ando, and T. Fujita Angiotensin II-Induced Insulin Resistance Is Enhanced in Adrenomedullin-Deficient Mice Endocrinology, August 1, 2004; 145(8): 3647 - 3651. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
N. C. Ward, J. Rivera, J. Hodgson, I. B. Puddey, L. J. Beilin, J. R. Falck, and K. D. Croft Urinary 20-Hydroxyeicosatetraenoic Acid Is Associated With Endothelial Dysfunction in Humans Circulation, July 27, 2004; 110(4): 438 - 443. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
T. Matsumoto, H. Takashima, N. Ohira, Y. Tarutani, Y. Yasuda, T. Yamane, S. Matsuo, and M. Horie Plasma level of oxidized low-density lipoprotein is an independent determinant of coronary macrovasomotor and microvasomotor responses induced by bradykinin J. Am. Coll. Cardiol., July 21, 2004; 44(2): 451 - 457. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
P. M Ridker, N. J. Brown, D. E. Vaughan, D. G. Harrison, and J. L. Mehta Established and Emerging Plasma Biomarkers in the Prediction of First Atherothrombotic Events Circulation, June 29, 2004; 109(25_suppl_1): IV-6 - IV-19. [Full Text] [PDF]
|
|
|
|
|
|
J. Gomez-Ambrosi, J. Salvador, and G. Fruhbeck Is hyperleptinemia involved in the development of age-related lens opacities? Am. J. Clinical Nutrition, May 1, 2004; 79(5): 888 - 889. [Full Text] [PDF]
|
|
|
|
|
|
C. S. Fox, L. Sullivan, R. B. D'Agostino Sr, and P. W.F. Wilson The Significant Effect of Diabetes Duration on Coronary Heart Disease Mortality: The Framingham Heart Study Diabetes Care, March 1, 2004; 27(3): 704 - 708. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 J. T. Lane Microalbuminuria as a marker of cardiovascular and renal risk in type 2 diabetes mellitus: a temporal perspective Am J Physiol Renal Physiol, March 1, 2004; 286(3): F442 - F450. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
T. L. Goodfriend and D. A. Calhoun Resistant Hypertension, Obesity, Sleep Apnea, and Aldosterone: Theory and Therapy Hypertension, March 1, 2004; 43(3): 518 - 524. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
E. Schwedhelm, A. Bartling, H. Lenzen, D. Tsikas, R. Maas, J. Brummer, F.-M. Gutzki, J. Berger, J. C. Frolich, and R. H. Boger Urinary 8-iso-Prostaglandin F2{alpha} as a Risk Marker in Patients With Coronary Heart Disease: A Matched Case-Control Study Circulation, February 24, 2004; 109(7): 843 - 848. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
T. L. Goodfriend, D. L. Ball, B. M. Egan, W. B. Campbell, and K. Nithipatikom Epoxy-Keto Derivative of Linoleic Acid Stimulates Aldosterone Secretion Hypertension, February 1, 2004; 43(2): 358 - 363. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 R S Vasan Cardiac function and obesity Heart, October 1, 2003; 89(10): 1127 - 1129. [Full Text] [PDF]
|
|
|
|
|
|
M. E. Widlansky, D. T. Price, N. Gokce, R. T. Eberhardt, S. J. Duffy, M. Holbrook, C. Maxwell, J. Palmisano, J. F. Keaney Jr, J. D. Morrow, et al. Short- and Long-Term COX-2 Inhibition Reverses Endothelial Dysfunction in Patients With Hypertension Hypertension, September 1, 2003; 42(3): 310 - 315. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J. V. Higdon and B. Frei Obesity and Oxidative Stress: A Direct Link to CVD? Arterioscler Thromb Vasc Biol, March 1, 2003; 23(3): 365 - 367. [Full Text] [PDF]
|
|
|
|
|
|
J. D. Morrow Is Oxidant Stress a Connection Between Obesity and Atherosclerosis? Arterioscler Thromb Vasc Biol, March 1, 2003; 23(3): 368 - 370. [Full Text] [PDF]
|
|
| |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||